Roche Reports Data from the P-III Clinical Evaluation of Columvi to Treat R/R Diffuse Large B-cell Lymphoma
Shots:
- The P-III (STARGLO) trial assesses the safety, tolerability & efficacy of Columvi (glofitamab) combined with gemcitabine + oxaliplatin (GemOx) vs rituximab + GemOx for treating r/r DLBCL patients administered with at least one previous line of therapy & not eligible for autologous stem cell transplant
- The 1EP of the study includes overall survival while the 2EPs include progression-free survival, complete response rate, objective response rate as well as the duration of objective response
- The study showed a consistent safety profile and reached the 1EP depicting those patients who received Columvi in combination with GemOx lived longer. The results will be highlighted at a future medical meeting
Ref: Roche | Image: Roche
Related News:- Roche’s Columvi (glofitamab) Receives EC’s Conditional Marketing Authorization for Relapsed or Refractory Diffuse Large B-cell Lymphoma
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
